RSAR: Harm Reductions Strategies for Opioids: Evaluating Naloxone Access
Past New Requirement Updated
- Agency
-
Food and Drug Administration
Department of Health and Human Services
- Solicitation expected
- Estimated value
- $250,000 to $700,000
- Set-aside
- No set-aside
Forecast facts
- Anticipated award
- NAICS code
- 923120 Administration of Public Health Programs
- Points of contact
-
- Christopher Scott christopher.scott@fda.hhs.gov
- tbd@fda.gov
Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.
About this forecast
The Department of Health and Human Services Food and Drug Administration is forecasting a new contract opportunity focused on Harm Reduction Strategies for Opioids, specifically evaluating Naloxone access and trends. The project is classified under the Administration of Public Health Programs (NAICS 923120) with an estimated solicitation release date of June 1, 2026, and a projected contract award date of August 1, 2026. This research-oriented contract aims to assess and analyze strategies related to reducing opioid-related harm through naloxone accessibility.
The primary point of contact for this opportunity is Christopher Scott, who can be reached at christopher.scott@fda.hhs.gov within the Food and Drug Administration. While specific award values and detailed performance requirements are not currently available, the contract is positioned as a strategic research initiative to understand and improve opioid harm reduction methodologies. Additional details about budget ranges, precise service timelines, and specific performance locations are pending further information from the agency.
Forecast text
RSAR: Harm Reductions Strategies for Opioids: Evaluating Naloxone Access and Trends
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast